12:00 AM
 | 
Nov 16, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Anifrolumab: Phase II data

A double-blind, international Phase II trial in 305 patients with seropositive moderate to severe SLE showed that 300 mg IV anifrolumab every 4 weeks met the primary endpoint of a greater proportion of patients achieving an SRI-4 response at day 169 with a sustained reduction of oral corticosteroid use between day 85 and 169 vs. placebo (34.4% vs. 17.6%, p=0.014). The 1,000 mg dose of anifrolumab every 4 weeks missed the primary endpoint vs. placebo (28.8%, p=0.063)....

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >